Copyright Reports & Markets. All rights reserved.

Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size, Status and Forecast 2021-2027

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
    • 1.2.2 Filgrastim
    • 1.2.3 Pefigrastim
    • 1.2.4 Lipefigrastim
  • 1.3 Market by Application
    • 1.3.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Application: 2016 VS 2021 VS 2027
    • 1.3.2 Oncology
    • 1.3.3 Blood Disease
    • 1.3.4 Other
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Perspective (2016-2027)
  • 2.2 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Growth Trends by Regions
    • 2.2.1 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Regions: 2016 VS 2021 VS 2027
    • 2.2.2 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Historic Market Share by Regions (2016-2021)
    • 2.2.3 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Forecasted Market Size by Regions (2022-2027)
  • 2.3 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Dynamic
    • 2.3.1 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Trends
    • 2.3.2 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Drivers
    • 2.3.3 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Challenges
    • 2.3.4 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Players by Revenue
    • 3.1.1 Global Top Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Players by Revenue (2016-2021)
    • 3.1.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Players (2016-2021)
  • 3.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue
  • 3.4 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Concentration Ratio
    • 3.4.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue in 2020
  • 3.5 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Key Players Head office and Area Served
  • 3.6 Key Players Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Solution and Service
  • 3.7 Date of Enter into Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Breakdown Data by Type

  • 4.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Historic Market Size by Type (2016-2021)
  • 4.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Forecasted Market Size by Type (2022-2027)

5 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Breakdown Data by Application

  • 5.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Historic Market Size by Application (2016-2021)
  • 5.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Forecasted Market Size by Application (2022-2027)

6 North America

  • 6.1 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2016-2027)
  • 6.2 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type
    • 6.2.1 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2016-2021)
    • 6.2.2 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2022-2027)
    • 6.2.3 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2016-2027)
  • 6.3 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application
    • 6.3.1 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2016-2021)
    • 6.3.2 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2022-2027)
    • 6.3.3 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2016-2027)
  • 6.4 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country
    • 6.4.1 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2016-2021)
    • 6.4.2 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2022-2027)
    • 6.4.3 United States
    • 6.4.4 Canada

7 Europe

  • 7.1 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2016-2027)
  • 7.2 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type
    • 7.2.1 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2016-2021)
    • 7.2.2 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2022-2027)
    • 7.2.3 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2016-2027)
  • 7.3 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application
    • 7.3.1 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2016-2021)
    • 7.3.2 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2022-2027)
    • 7.3.3 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2016-2027)
  • 7.4 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country
    • 7.4.1 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2016-2021)
    • 7.4.2 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2022-2027)
    • 7.4.3 Germany
    • 7.4.4 France
    • 7.4.5 U.K.
    • 7.4.6 Italy
    • 7.4.7 Russia
    • 7.4.8 Nordic

8 Asia-Pacific

  • 8.1 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2016-2027)
  • 8.2 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type
    • 8.2.1 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2016-2021)
    • 8.2.2 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2022-2027)
    • 8.2.3 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2016-2027)
  • 8.3 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application
    • 8.3.1 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2016-2021)
    • 8.3.2 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2022-2027)
    • 8.3.3 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2016-2027)
  • 8.4 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Region
    • 8.4.1 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Region (2016-2021)
    • 8.4.2 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Region (2022-2027)
    • 8.4.3 China
    • 8.4.4 Japan
    • 8.4.5 South Korea
    • 8.4.6 Southeast Asia
    • 8.4.7 India
    • 8.4.8 Australia

9 Latin America

  • 9.1 Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2016-2027)
  • 9.2 Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type
    • 9.2.1 Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2016-2021)
    • 9.2.2 Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2022-2027)
    • 9.2.3 Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2016-2027)
  • 9.3 Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application
    • 9.3.1 Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2016-2021)
    • 9.3.2 Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2022-2027)
    • 9.3.3 Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2016-2027)
  • 9.4 Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country
    • 9.4.1 Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2016-2021)
    • 9.4.2 Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2022-2027)
    • 9.4.3 Mexico
    • 9.4.4 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2016-2027)
  • 10.2 Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type
    • 10.2.1 Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2016-2021)
    • 10.2.2 Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2022-2027)
    • 10.2.3 Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2016-2027)
  • 10.3 Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application
    • 10.3.1 Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2016-2021)
    • 10.3.2 Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2022-2027)
    • 10.3.3 Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2016-2027)
  • 10.4 Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country
    • 10.4.1 Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2016-2021)
    • 10.4.2 Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2022-2027)
    • 10.4.3 Turkey
    • 10.4.4 Saudi Arabia
    • 10.4.5 UAE

11 Key Players Profiles

  • 11.1 Amgen
    • 11.1.1 Amgen Company Details
    • 11.1.2 Amgen Business Overview
    • 11.1.3 Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Introduction
    • 11.1.4 Amgen Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2016-2021)
    • 11.1.5 Amgen Recent Development
  • 11.2 Kyowa Kirin
    • 11.2.1 Kyowa Kirin Company Details
    • 11.2.2 Kyowa Kirin Business Overview
    • 11.2.3 Kyowa Kirin Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Introduction
    • 11.2.4 Kyowa Kirin Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2016-2021)
    • 11.2.5 Kyowa Kirin Recent Development
  • 11.3 Chugai Pharmaceutical
    • 11.3.1 Chugai Pharmaceutical Company Details
    • 11.3.2 Chugai Pharmaceutical Business Overview
    • 11.3.3 Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Introduction
    • 11.3.4 Chugai Pharmaceutical Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2016-2021)
    • 11.3.5 Chugai Pharmaceutical Recent Development
  • 11.4 Novartis
    • 11.4.1 Novartis Company Details
    • 11.4.2 Novartis Business Overview
    • 11.4.3 Novartis Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Introduction
    • 11.4.4 Novartis Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2016-2021)
    • 11.4.5 Novartis Recent Development
  • 11.5 Teva
    • 11.5.1 Teva Company Details
    • 11.5.2 Teva Business Overview
    • 11.5.3 Teva Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Introduction
    • 11.5.4 Teva Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2016-2021)
    • 11.5.5 Teva Recent Development
  • 11.6 Pfizer
    • 11.6.1 Pfizer Company Details
    • 11.6.2 Pfizer Business Overview
    • 11.6.3 Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Introduction
    • 11.6.4 Pfizer Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2016-2021)
    • 11.6.5 Pfizer Recent Development
  • 11.7 Merck
    • 11.7.1 Merck Company Details
    • 11.7.2 Merck Business Overview
    • 11.7.3 Merck Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Introduction
    • 11.7.4 Merck Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2016-2021)
    • 11.7.5 Merck Recent Development
  • 11.8 Dong-A Socio
    • 11.8.1 Dong-A Socio Company Details
    • 11.8.2 Dong-A Socio Business Overview
    • 11.8.3 Dong-A Socio Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Introduction
    • 11.8.4 Dong-A Socio Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2016-2021)
    • 11.8.5 Dong-A Socio Recent Development
  • 11.9 Intas
    • 11.9.1 Intas Company Details
    • 11.9.2 Intas Business Overview
    • 11.9.3 Intas Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Introduction
    • 11.9.4 Intas Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2016-2021)
    • 11.9.5 Intas Recent Development
  • 11.10 GenSci
    • 11.10.1 GenSci Company Details
    • 11.10.2 GenSci Business Overview
    • 11.10.3 GenSci Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Introduction
    • 11.10.4 GenSci Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2016-2021)
    • 11.10.5 GenSci Recent Development
  • 11.11 Dr. Reddy
    • 11.11.1 Dr. Reddy Company Details
    • 11.11.2 Dr. Reddy Business Overview
    • 11.11.3 Dr. Reddy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Introduction
    • 11.11.4 Dr. Reddy Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2016-2021)
    • 11.11.5 Dr. Reddy Recent Development
  • 11.12 Amoytop
    • 11.12.1 Amoytop Company Details
    • 11.12.2 Amoytop Business Overview
    • 11.12.3 Amoytop Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Introduction
    • 11.12.4 Amoytop Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2016-2021)
    • 11.12.5 Amoytop Recent Development
  • 11.13 North China Pharmaceutical
    • 11.13.1 North China Pharmaceutical Company Details
    • 11.13.2 North China Pharmaceutical Business Overview
    • 11.13.3 North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Introduction
    • 11.13.4 North China Pharmaceutical Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2016-2021)
    • 11.13.5 North China Pharmaceutical Recent Development
  • 11.14 SL Pharm
    • 11.14.1 SL Pharm Company Details
    • 11.14.2 SL Pharm Business Overview
    • 11.14.3 SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Introduction
    • 11.14.4 SL Pharm Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2016-2021)
    • 11.14.5 SL Pharm Recent Development
  • 11.15 Hayao Group
    • 11.15.1 Hayao Group Company Details
    • 11.15.2 Hayao Group Business Overview
    • 11.15.3 Hayao Group Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Introduction
    • 11.15.4 Hayao Group Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2016-2021)
    • 11.15.5 Hayao Group Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Scope and Market Size
    Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

    Segment by Type
    Filgrastim
    Pefigrastim
    Lipefigrastim

    Segment by Application
    Oncology
    Blood Disease
    Other

    By Region
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia
    Latin America
    Mexico
    Brazil
    Rest of Latin America
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of MEA

    By Company
    Amgen
    Kyowa Kirin
    Chugai Pharmaceutical
    Novartis
    Teva
    Pfizer
    Merck
    Dong-A Socio
    Intas
    GenSci
    Dr. Reddy
    Amoytop
    North China Pharmaceutical
    SL Pharm
    Hayao Group

    Buy now